Detalhe da pesquisa
1.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Lancet
; 401(10373): 269-280, 2023 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709073
2.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value Health
; 27(5): 607-613, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311180
3.
Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus.
Future Oncol
; 20(11): 703-715, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38318719
4.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Br J Cancer
; 129(1): 38-45, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120671
5.
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Haematologica
; 109(2): 676-681, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37259556
6.
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Clin Cancer Res
; 29(2): 331-340, 2023 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36378548
7.
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
Hemasphere
; 7(11): e963, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37908862
8.
Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.
Cancer Med
; 12(9): 10612-10624, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37021939
9.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
Lancet Haematol
; 10(9): e735-e746, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37517413
10.
Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).
BMC Cancer
; 12: 415, 2012 Sep 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22992303
11.
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 22(1): 52-59, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34454850
12.
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
Leukemia
; 36(9): 2261-2268, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35869266
13.
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies.
Clin Lymphoma Myeloma Leuk
; 21(12): 823-830, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34417162
14.
Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world Implications.
Hemasphere
; 6(10): e778, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36204692
15.
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.
Drug Des Devel Ther
; 11: 1719-1728, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28670108
16.
Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors.
J Clin Oncol
; 22(8): 1373-81, 2004 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15007085
17.
Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101.
Clin Cancer Res
; 8(5): 1028-37, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12006515
18.
Anal cancer: an HIV-associated cancer.
Hematol Oncol Clin North Am
; 17(3): 859-72, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12852659
19.
Altered clinical course of malignant melanoma in HIV-positive patients.
Arch Dermatol
; 138(6): 765-70, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12056957
20.
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
J Clin Pharmacol
; 52(5): 691-703, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21953571